4.5 Article

The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction

Journal

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Volume 71, Issue 3, Pages 379-392

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0091-3057(01)00698-0

Keywords

glutamate; metabotropic receptor; N-methyl-D-aspartate; fear learning; fear-potentiated startle; anxiety; amygdala; D-cycloserine

Funding

  1. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059906, P50MH052384, P50MH058922, R01MH057250, R37MH047840, R01MH047840] Funding Source: NIH RePORTER
  2. NIMH NIH HHS [MH 58922, MH 52384, MH 47840, MH 59906, MH 57250] Funding Source: Medline

Ask authors/readers for more resources

Using a paradigm known as fear-potentiated startle, we have examined the neurobiological substrates of Pavlovian fear conditioning. In these experiments, rats are trained to fear an initially neutral stimulus by pairing that stimulus with shock. The amount of fear elicited by the stimulus [i.e., now a conditioned stimulus (CS)] is later assessed by presenting startle-eliciting noise bursts both in the presence and also the absence of the CS. After training, startle responses are typically greater in the presence of the CS. Findings reviewed here suggest that amygdala N-methyl-D-aspartate (NMDA) receptors play a key role in triggering the neural changes that support fear learning and also the loss of fear that accompanies extinction training. Amygdala(+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors also participate in fear learning. However, unlike NNMA receptor antagonists, AMPA receptor antagonists also block fear-potentiated startle when infused prior to testing. Very recent data indicate that glutamate metabotropic Group II receptor agonists also block fear learning when infused into the amygdala prior to training, and block fear-potentiated startle when infused prior to testing. A fuller understanding of the role of amygdala glutamate systems in fear and fear learning may suggest novel pharmacological approaches to the treatment of clinical anxiety disorders. (C) 2002 Elsevier Science Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available